Immunicum announced positive results from its Phase I/II clinical trial today. The trial examined the safety and tolerability of Immunicum’s lead candidate, ilixadencel, in combination with tyrosine kinase inhibitors (TKIs) in six patients with Gastrointestinal Stromal Tumors (GIST), the most common sarcoma that is highly resistant to conventional radio- and chemotherapy.
The results confirmed the company’s previous studies, showing that ilixadencel had a favorable safety profile in combination with several TKIs. Based on the analysis of the secondary clinical trial endpoints, there are also initial signals of clinical benefit in two patients who partially responded to the treatment.
Peter Suenaert, MD, PhD, Chief Medical Officer at Immunicum, explained that ‘Although this study was conducted in a small group of patients, it is important to note that they all were at an advanced disease stage, meaning that both the safety data and the signals of clinical response are encouraging.’